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Abstract
There is an urgent need for biomarkers in plasma to identify Alzheimer’s disease (AD). It has previously been shown that a
signature of 18 plasma proteins can identify AD during pre-dementia and dementia stages (Ray et al, Nature Medicine,
2007). We quantified the same 18 proteins in plasma from 174 controls, 142 patients with AD, and 88 patients with other
dementias. Only three of these proteins (EGF, PDG-BB and MIP-1d) differed significantly in plasma between controls and AD.
The 18 proteins could classify patients with AD from controls with low diagnostic precision (area under the ROC curve was
63%). Moreover, they could not distinguish AD from other dementias. In conclusion, independent validation of results is
important in explorative biomarker studies.
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Introduction
Alzheimer’s disease (AD) is the major cause of dementia and a
great medical and socioeconomic problem worldwide. As popula-
tions get older, the prevalence of AD will increase considerably
during the coming decades [1]. The pathological characteristics of
AD are senile plaques and neurofibrillary tangles, containing
aggregated amyloid b (Ab) and hyperphosphorylated tau protein,
respectively [1,2]. Ab accumulation is thought to start many
decades before symptoms occur [3]. During the last few years, it
has become more apparent that disease-modifying therapies for
AD are more likely to be successful if initiated during the early
stages of the disease when neurodegeneration is not yet too severe
[4,5]. Therefore, biomarkers are urgently needed to correctly
identify subjects affected by AD before they have developed
dementia [5,6]. Cerebrospinal fluid biomarker can identify
prodromal AD with acceptable accuracy [7–9]. However, plasma
is much easier obtained than cerebrospinal fluid. Therefore, it was
a major breakthrough when Ray and collaborators found that a
pattern of 18 proteins in plasma could classify samples from AD
and controls with almost 90% accuracy [10]. The same plasma
proteins could also predict the patients with mild cognitive
impairment who would later develop AD. The study comprised of
259 plasma samples obtained from in total 7 clinical centres [10].
In the present study, we evaluated the diagnostic value of the
same 18 proteins as Ray et al [10], using 433 plasma samples
obtained at Ska ˚ne University Hospital, Sweden, from 174 controls,
142 patients with AD, 29 patients with depression, and 88 patients
with other types of dementia than AD (i.e 37 with Lewy Body
dementia, 11 with Parkinson’s disease with dementia, 22 with
frontotemporal dementia, 18 with vascular dementia).
Materials and Methods
Collection and processing of human plasma samples
The study population was recruited at the memory disorder
clinic, Ska ˚ne University Hospital, Malmo ¨, Sweden. The patients
underwent thorough standard examinations conducted by a
trained physician, including neurological, physical and psychiatric
examinations. The patients who during clinical follow-up received
a diagnosis of AD had to meet the DSM-IIIR criteria of dementia
[11] and the criteria of probable AD defined by NINCDS-
ADRDA [12]. Subjects who were diagnosed as having vascular
dementia (VaD) fulfilled the DSM-IIIR criteria of dementia and
the requirements for probable VaD by NINDS-AIREN [13] or
the recommendations by Erkinjuntti and co-workers for VaD of
the subcortical type [14]. For patients who developed dementia
with Lewy bodies (DLB) or frontotemporal dementia, the con-
sensus criteria by McKeith and collaborators [15] and McKhann
and colleagues were used [16], respectively. The healthy volunteers
had no memory complaints or other cognitive symptoms,
preservation of general cognitive function, and no active neurolog-
ical or psychiatric diseases.
The study was conducted in accordance with the Helsinki
Declaration and approved by the ethics committee of Lund
University, Sweden. All subjects gave informed written consent.
Non-fasting plasma was collected between 9 and 11 am. After
venipuncture, blood was collected in tubes prepared with EDTA
to prevent coagulation. Samples were centrifuged, and plasma was
removed from the tubes leaving 1 ml of plasma to avoid
contamination of plasma with blood cells including trombocytes.
Within one hour from venipuncture the plasma was frozen in
polypropylene tubes at 280uC until biochemical analysis.
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QuantibodyH Human Costum Cytokine Antibody Array was
performed by RayBiotech (as per company description) on blinded
samples for the following markers; ANG-2I, CAM-1, IGFBP-6,
PARC, PDGF-BB, RANTES, EGF, G-CSF, GDNF, IL-1a, IL-3,
IL-8, IL-11, MCP-3, M-CSF, MIP-1d, TNFa, and TRAIL R4. A
positive control (four biotin-labelled bovine IgG spot) was included
on each array and used for inter- and intra-slide normalization.
For a quadruplicate spot, outliers as value above 30% over the
median, was excluded. All samples were analyzed in a single run to
minimize variation.
Selected cytokines (M-CSF and TNF-a) were quantified in
triplicates using Meso Scale Discovery (MSDH, Gaithersburg,
MD) electrochemoluminescence assays using a modification of the
manufacturer’s protocol. 30 ul was used as the sample volume and
a 10-point standard curve was used, ranging from 2500 pg/ml
to 0 pg/ml. The sample and calibrator were incubated on the
MSD plate for 3 h (instead of 2 h), followed by a wash (as per
manufacturer’s recommendation). The MSD plate was then
incubated with detection antibody solution for 3 h (instead of
2 h) before wash and read as per manufacturer’s recommendation.
Results were analyzed on a SECTOR
TM 6000 instrument (MSD).
The operator was unaware of the disease state of each sample
during processing and statistical analysis was performed indepen-
dently.
Statistical analysis
The statistical analyses were accomplished using SPSS for
Windows, version 18.0.1 (SPSS Inc/IBM, Chicago, IL, USA). To
compare demographic and plasma data between groups, non-
parametric Kruskal-Wallis tests were performed followed by
Mann-Whitney U-tests for continuous variables. Pearson’s x
2 test
was used for dichotomous variables.
To assess the ability of the plasma data to separate groups (AD
vs. Controls or AD vs. other dementia) multiple logistic regression
[17], artificial neural network (ANN) [18] and nearest shrunken
centroid [19] classification models were used. The latter was the
method used by Ray et al. Bagging ensembles [20] of standard
multi-layer perceptrons with one hidden layer were used in the
ANN models. The size of the ensemble was set to 30 and the
number of hidden nodes of the individual networks in the
ensemble was two. No effort was made to tune these parameters.
The nearest shrunken centroid method was implemented using the
R package pamr. The area under the ROC curve (AUC) was used
Table 1. Subject demographics and plasma protein levels.
Controls (n=174) Depr (n=29) AD (n=142) FTD (n=22) VaD (n=18) PDD (n=11) DLB (n=37)
Mean age (range) 74 (62–99) 59 (42–76) 76
a,b (56–87) 62 (43–78) 76 (56–84) 72 (62–81) 74 (54–85)
Women 117 15 40
c 11 14 5 26
MMSE 2960,1 2860,4 2160,4
d,e 2261,1 2260,8 2062,0 2160,9
ANG-2 24446143 17106232 23066284 20436320 24106527 17896535 23356341
ICAM-1 224692 5 0 631 21669 222628 220622 162616 204615
IGFBP-6 382613 366621 377613 337619 373640 391651 379617
PARC (CCL18) 4362,7 4066,0 4062,4 3865,1 3967,9 3365,3 4163,9
PDGF-BB 43856288 633961122 57016427
f 58966706 930263278 855763513 579861431
RANTES (CCL5) 1860,7 2061,5 2060,7 2061,3 2363,2 1962,3 1861,3
EGF 541631 665665 706632
g 825679 7996158 9076117 580649
G-CSF 5463,1 4165,1 57665 6 610 53612 56613 4263,9
GDNF 103633 86634 3226262 79615 41611 34612 4566,5
IL-1a 1362,4 11,263,2 26617 1161,7 8,561,9 1062,0 9,561,3
IL-3 44615 2969,1 87663 3266,3 1463,8 1564,1 2266,0
IL-8 (CXCL8) 1161,0 8,560,8 1060,5 1261,9 1061,4 1161,2 1060,8
IL-11 236627 185678 249634 249653 260674 1586563 263649
MCP-3 (CCL7) 5164,8 4766,4 82630 5166,8 52612 6768,2 4266,1
M-CSF 1,060,2 1,360,7 160,3 1,260,37 0,7760,51 1,260,5 1,060,4
MIP-1d (CCL15) 2361685 23226229 28456142
h 24526200 23836312 31546453 31446348
TNF-a 2364,6 1562,5 1761,3 1762,6 1562,8 1662,6 1662,0
TRAILR4 36615 1264,3 1696157 1767,1 1369,1 3,162,3 9,563,3
Table 1. Values are given in ng/L, except for ICAM-1, IGFBP-6, PARC and RANTES for which concentrations are given in mg/L.
When comparing AD vs 1) Controls, 2) Depression and 3) other dementias the following significant changes were observed:
aAD vs control p=0.01,
bAD vs depression p,0.001, AD vs other dementias p=0.01.
cAD vs depression p=0.034.
dAD vs control p,0.001,
eAD vs depression p=0.001.
fAD vs control p=0.004.
gAD vs control p,0.001.
hAD vs control p=0.011 (Kruskal–Wallis one-way analysis of variance by ranks followed by Mann-Whitney U test).
Abbreviations: Depr, depression; AD, Alzheimers disease; FTD, frontotemporal lobe dementia; VaD, vascular dementia; PDD, Parkinson’s disease with dementia;
DLB=dementia with Lewy bodies.
doi:10.1371/journal.pone.0029868.t001
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three models, 10-fold cross-validation was used to estimate true
AUC values. The cross-validation procedure was repeated 100
times, with random 10-fold splits each time, in order to decrease
random fluctuations.
Results
In table 1 we present the demographic data and levels of the 18
plasma proteins obtained when using QuantibodyH Human
Costum Cytokine Antibody Array (RayBiotech). The subjects
affected by AD were slightly older than the controls and the group
affected by other forms of dementias (p#0.01). Only three proteins
of the 18 proteins, (EGF, PDG-BB and MIP-1d), were found to be
significantly altered in plasma from AD patients when compared
to controls (table 1). None of the proteins differed between the AD
group and the group with other dementias than AD. Analyses of
two cytokines (M-CSF and TNF-a) with ELISA technology
verified that there were no statistical differences between AD
and control plasma samples (in control plasma, n=148, M-CSF
levels were 21.8260.87 ng/L and TNF-a levels were 1.906
0.14 ng/L, in AD plasma, n=148, the corresponding levels were
24.0360.71 and 1.8560.06 ng/L respectively).
When classifying the AD group from the controls, the cross-
validation AUC for the logistic regression model was 0.60 using all
18 proteins. The corresponding AUC for the ANN model and the
nearest shrunken centroid classifier was 0.63. When only using the
three proteins that differed significantly between groups (i.e. EGF,
PDG-BB and MIP-1d), as inputs to the classifiers, the AUC
increased to 0.66 for all three models.
A worse performance was obtained when classifying the group
with AD from the group with other forms of dementia than AD.
Using all plasma proteins the cross-validation AUC was below 0.5
indicating no classification ability at all. This was true for all three
models. The best individual protein in terms of AUC performance
was TRAIL-R4 with an AUC of 0.61 (cross-validation result).
To further illustrate the limitation of the 18 plasma protein
panel to differentiate AD from the controls and other dementia
groups, multidimensional scaling (MDS) plots were produced
(figure 1). These plots show a large degree of overlap between the
diagnostic groups.
Discussion
Characterizing protein markers in plasma has created optimism
for finding detectable disease-specific pattern of changes. A
biomarker panel of eighteen plasma proteins were shown in
2007 to classify blinded samples from AD and control subjects
with close to 90% accuracy and to identify patients who had mild
cognitive impairment that progressed to Alzheimer’s disease [10].
The study was comprised of 259 plasma samples obtained from in
total seven different clinical centres.
Interestingly, when re-analysing the same data set, originally
obtained from the Ray et al study, a subset of plasma proteins (as
z-scores of plasma proteins) resulted in good diagnostic accuracy
[21]. However, following up on these results, using bead-based
multiplex technology, Soares and co-workers have shown that
when using a subset of the proteins included in the original 18
protein panel a diagnostic accuracy of only 61% was obtained
when differentiating cases with AD from controls [22]. Later
Rocha de Paula et al. proposed, using the original data set
provided by Ray et al, that including pair-wise differences of z-
score values to the mathematical method, could collectively
provide a good discrimination value [23].
In the present study we found that the 18 plasma protein panel
could classify samples from AD and controls with an AUC of only
63%, indicating that this protein panel cannot be used in the
clinical diagnostic work-up of AD. The same protein panel could
not distinguish cases with AD from subjects affected by other
forms of dementia. In addition, the pattern of protein changes
observed in the present study was not the same as in Ray et al.
More specifically, in the training set described in the study by Ray
Figure 1. Multidimensional scaling plots (MDS) for the data. The left figure shows a MDS projection to 2 dimensions, using all 18 proteins, for
the AD and the Control groups. The right figure is the corresponding plot for the AD and the other dementias group.
doi:10.1371/journal.pone.0029868.g001
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seen to be reduced in AD cases. In contradiction to this, in the
present study the plasma levels of these proteins were increased in
the AD cases. Similarly, Marksteiner et al have found that plasma
MIP-1d and EGF are increased in AD patients when compared to
patients affected by depression [24].
Several of the 18 proteins included in the biomarker panel are
involved in the immune response [10]. There are, however,
important caveats to the use of plasma immune markers as
biomarkers of disease progression or diagnostic predictors. AD is a
slowly progressive disorder and systemic changes in the blood are
likely to be subtle and difficult to monitor. There are also technical
limitations in assaying low abundant cytokines and many factors
likely influence plasma immune markers, such as concomitant
infection and inflammatory illness. Furthermore, many cytokines
has been shown to display diurnal variation [25] and different
handlings as well as storage of samples are known to affect the
levels of many biomarkers. Therefore, standardization of pre-
analytical procedures is vital to obtain reproducible results. To
increase the possibility of successful reproduction of biomarker
studies in the future the handling of samples should be carefully
described, including data describing the time from venipuncture to
minus 80 freezer storage, time of day that venipuncture was
performed and if samples were collected fasting or non-fasting.
Moreover, when using samples from different clinical centres all
diagnostic groups (including controls) need to be obtained from
each clinical centre in order to be able to investigate potential
variations in biomarker levels between different clinical sites.
A limitation of this study is that the array-based method used is
a potentially unreliable tool to disprove the original study by Ray
et al, who also used a similar and non-validated method. However,
in the present study we selected two cytokines for confirmation
measurements with a standardized ELISA method, and again
found no statistical differences between control and AD samples.
Our results indicate that multiplex platforms might be
important for biomarker discovery, but validation of the results
using new patient cohorts as well as other analytical techniques are
vital. At least two patient-control cohorts with all important
diagnostic groups present in each will likely be needed to verify
obtained data. Importantly, recent data show that highly cited
biomarker studies often report larger effect estimates than are
reported in subsequent meta analyses [26]. This further strength-
ens our notion that validation is crucial in biomarker research.
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